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Summary. The acute effect of a single oral dose of is- 
radipine 5 mg on blood pressure, renal haemodynamics, 
electrolyte xcretion and plasma renin activity was stud- 
ied in 10 healthy males. 
Isradipine did not produce a significant change in sys- 
tolic or diastolic blood pressure, and glomerular filtration 
rate, renal plasma flow, renal vascular esistance, and uri- 
nary albumin excretion remained constant. There was a 
marked natriuretic and diuretic effect about 1-3 h after is- 
radipine. Plasma renin activity showed a slight, insignifi- 
cant increase i h after dosing. Uric acid clearance and 132- 
microglobulin excretion showed no significant changes, 
despite an increase in sodium clearance, suggesting an ad- 
ditional mechanism of action other than the proximal tu- 
bular natriuretic effect of isradipine in normotensive vol- 
unteers. 
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Oral administration of the calcium channel-blocking 
drugs nifedipine, verapamil, diltiazem, nitrendipine, and 
nicardipine is known acutely to increase salt and water ex- 
cretion, without affecting glomerular filtration rate 
(GFR) and renal plasma flow (RPF); diltiazem may in- 
crease GFR and RPE These agents have no consistent ef- 
fect on any of the measured components of the renin-an- 
giotensin-aldosterone system (nifedipine may acutely 
increase plasma renin activity, PRA; [1]). However, no 
sustained effect of most of the calcium entry-blocking 
drugs on salt and water excretion has been demonstrated 
in patients [1]. 
Isradipine, a new dihydropyridine calcium antagonist, 
has been shown to be effective in the treatment of pa- 
tients with hypertension or angina pectoris [2-4]. A smal- 
ler negative inotropic effect and less reflex tachycardia 
compared to nifedipine make isradipine a promising 
compound in the treatment of patients with coronary ar- 
tery disease and congestive heart failure [5]. Krusell et al. 
[6] demonstrated an increase in GFR, RPF, sodium clear- 
ance, and lithium clearance, and a decrease in renal vas- 
cular resistance in essential hypertensive patients after 
3.5 months of treatment with 17.5 mg. d-1 isradipine. 
However, after 2 years of isradipine treatment 
(13.3 mg-d-1) GFR and RPF were no longer significant- 
ly increased; data for lithium clearance and renal 
vascular esistance were not given [7]. Persson et al. [8] 
demonstrated an increase in RPF and no significant 
change in GFR or sodium excretion in hypertensive pa- 
tients after 9 weeks on isradipine (15 mg-d-a),  whereas 
Rupoli et al. [9] demonstrated no change in GFR and 
PPF, but an increase in sodium excretion after acute ad- 
ministration of 2.5 to 7.5 mg isradipine in essential hyper- 
tensives. 
The aim of the present study was to evaluate the acute 
effects of isradipine on renal haemodynamics with special 
regard to sodium excretion, proximal tubular function and 
the renin-angiotensin-aldosterone system in normoten- 
sive subjects. 
Subjects and methods 
10 healthy, male, normotensive subjects [mean age 26 (4) y, mean 
weight 76 (6) kg, mean height 182 (3) cm] participated in the study 
after giving their informed consent. The protocol was approved by 
the local Ethical Committee. None was taking any other drug. They 
all received extensive dietary counseling inorder to achieve asalt in- 
take of about 120-140 mmol/day during the study periods. 
After an overnight fast the subject was placed in the supine posi- 
tion, cannulae were inserted into antecubital veins on both sides and 
the subject drank 500 ml water every 60 min. Inulin clearance and 
PAH (para-aminohippurate) clearance were measured by the con- 
stant infusion technique after a loading dose at 08.30 h (120 mg inu- 
lin. rain-~, m-2 and 40 mg PAH. min-1, m-2 during 30 rain as load- 
ing dose; 24.5 mg inulin, rain- t. m - 2 and 14.6 mg PAH- rain - ~. m -2 
during 330 rain as constant infusion). At 10.30 h the subject received 
either 5 mg isradipine or placebo (the examination was repeated 
after 7 days with the other substance) in a crossover, double-blind 
fashion. Baseline renal haemodynamic and laboratory measure- 
ments were made during two 30 rain periods from 09.30 to 10.30 h 
(-1-0 h in Table 1). Subjects voided spontaneously every 30 rain. 
PRA and plasma ldosterone concentration (PAC) were measured 
by commercially available kits (Renin MAIA, Fa. Serono Diagnos- 
tika GmbH, Freiburg, FRG; Coat-A-Count Aldosteron, Fa. H. Bier- 
mann Medizinische Systeme GmbH, Bad Nauheim, FRG). Serum 
and urinary potassium, sodium, calcium, creatinine, and uric acid 
were measured by routine laboratory methods. Plasma isradipine 
was measured by a radioimmunoassay. S stolic (SBP) and diastolic 
blood pressure (DBP) were measured every 30 min throughout the 
study with a sphygmomanometer. 
Statistical evaluation was done by means of the paired t-test. 
Data are given as mean with (SEM). All clearances were normalized 
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Table L Renat plasma flow (RPF), glomerular filtration rate (GFR), sodium clearance (CL Na), urine volume xcretion (UV), uric acid clear- 
ance (CL u), albumin excretion (UAE), and 132-microglobulin excretion ([~2ME) after oral administration f 5 mg isradipine (I) or placebo (C) 
Time after drug administration 0 h
-1-0h ~ lh  l~h ~3h 34  h 
GFR (ml.min -1) I 121(3) 86(6) a 104(7) 89(5) 86(6) 
C 108 (13) 111 (10) 94 (10) 105 (6)  100 (8)  
RPF (ml. min 1) I 684 (55) 559 (36) 644 (49) 582 (41) 548 (29) 
C 565 (57) 620 (67) 517 (38) 560 (40) 573 (56) 
CLNa (ml. min-1) I 2.2 (0.3) 2.7 (0.5) 3.3 (0.3) b 2.8 (0.3) a 2.4 (0.2) 
C 1.9 (0.2) 2.3 (0.2) 2.2 (0.3) 2.2 (0.2) 2.2 (0.2) 
U-V (ml-min -~) I 13.2 (1.0) 12.5 (0.9) 14.0 (1.1)" 11.2 (1.1) 10.1 (1.1) 
C 12.2 (1.5) 13.3 (1.5) 10.6 (1.3) 10.5 (1.1) 11.0 (1.5) 
CL u (ml, min- 1) I 9.7 (0.9) 7.5 (0.9) 9.8 (0.5) 8.1 (0.5) 7.4 (0.7) 
C 8.7 (0.8) 9.3 (1.0) 8.6 (0.9) 8.2 (0.8) 8.1 (0.8) 
UAE (ug. min 1) I 16.6 (3.8) 10.7 (2.5) 12.0 (2.5) 10.5 (2.1) 10.3 (2.2) 
C 18.1 (4.5) 14.5 (2.9) 12.2 (2.9) 11.9 (2.6) 10.4 (2.3) 
U[32ME (mg. h 1) I 135 (1.3) 11.9 (1.5) 13.1 (0.9) 11.7 (1.0) 11.6 (1.2) 
C 13.3 (1.7) 13.0 (1.3) 11.3 (1.2) 12.4 (1.1) 11.9 (1.7) 
" P < 0.05 in comparison toplacebo; b p < 0.01 in comparison to placebo 
Table 2. Systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), plasma ldosterone concentration (PAC), and plas- 
ma renin activity (PRA) after oral administration f 5 mg isradipine (I) or placebo (C) 
Time after drug administration at 0 h 
Oh lh  2h 3h 4h 
SBP(mmHg) I 126 (4) 122 (5) 126 (4) 123 (5) 127 (4) 
C 130 (5) 127 (4) 122 (3) 122 (3) 124 (4) 
DBP(mmHg) I 83 (2) 77 (2) 81 (2) 79 (3) 81 (2) 
C 84 (3) 85 (2) 80 (2) 83 (2) 83 (3) 
HR(beats..min -1) I 67 (3) 69 (3) 68 (3) 70 (3) 68 (3) 
C 66 (3) 67 (3) 64 (2) 65 (2) 65 (2) 
PAC(pg.m1-1) I 78 (6) 70 (7) 70 (8) 77 (11) 71 (8) 
C 91 (9) 77 (12) 70 (15) 74 (12) 69 (8) 
PRAAI  I 0,9 (0.2) 1.4 (O.3) 1.3 (O.3) 1.2 (0.3) 1.4 (0.3) 
(ng,ml-l .h -1) C 1,0 (0.3) 1.0 (0.3) 1.4 (0.3) 1.1 (0.4) 1.5 (0.5) 
P < 0.05 in comparison to placebo 
to 1.73 m 2 body surface. Mean blood pressure was calculated as dias- 
tolic blood pressure plus one third of the pulse pressure. Inulin dear- 
ance and PAH dearance were taken as measures of GFR and RPE 
Renal vascular esistance (RVR) was calculated as mean blood 
pressure/RBF and RBF as RPF/1-haematocrit. Filtration fraction 
(FF) was calculated as GFR/RPE 
Results 
GFR, RPF, sodium and urate clearance, urine volume, and 
urinary excretion of  albumin and [3-2-microglobulin are 
displayed in Table 1. Urinary sodium clearance and urine 
volume were significantly higher after isradipine than 
placebo, whereas RPF, uric acid clearance and albumin and 
[32-microglobulin excretion were not significantly differ- 
ent. GFR remained unchanged uring the course of the 
study except for a transient decrease from 0-1 h after is- 
radipine. Systolic and diastolic blood pressure, heart rate, 
PRA and PAC were not Significantly changed by isradipine 
(Table 2). In addition, creatinine clearance, as another 
measure of GFR,  as well as calcium and potassium clear- 
ance, filtration fraction and renal vascular esistance did 
not change during the course of our study. 
Plasma isradipine levels (ng. ml -t) were 2.08 (0.66), 
3.44 (0.46), 3.02 (0.44), 2.75 (0.45), 2.13 (0.32), 1.94 (0.22), 
1.75 (0.14), 1.61 (0.15) at 0.5,1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0 h 
after intake of 5 mg isradipine. 
Three subjects receiving isradipine complained of 
headache. No other side effects were reported. 
Discussion 
The oral administration of 5 mg isradipine had no signifi- 
cant effect on blood pressure or heart rate in healthy, nor- 
motensive controls, whereas SBP and DBP were signifi- 
cantly howered by it in essential hypertensive patients 
[6--9], and heart rate was either unchanged [7, 8] or in- 
creased [6, 9]. Lederbal le Pedersen et al. [10] did not find 
a fall in blood pressure in normotensive controls after ad- 
ministration of nifedipine, despite a marked effect in 
hypertensive patients. 
The plasma concentrations of isradipine here were in 
accordance with other results [11, 12], demonstrating ab- 
sorption and stable plasma levels within 30 min of admin- 
istration. 
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The present results demonstrate an increase in sodium 
excretion 1 to 3 h after oral administration of 5 mg is- 
radipine in normotensive subjects, and an increase of 
urine volume after i to 2 h. The results are in accordance 
with other studies, in which increases in sodium excretion 
[6, 7, 9] and urine volume [6, 9] were seen in essential 
hypertensive patients, but they are not fully in agreement 
with reports in which increases in sodium excretion [8] and 
urine volume [7, 8] did not reach statistical significance. 
GFR (except for a transient decrease in the first h after 
drug intake), RPF, RVR and FF remained unchanged 
throughout he 5 h of observation in accordance with 
some findings in hypertensive patients (GFR [7-9], RPF 
[7, 9], FF [6, 7]), but in contrast to others (increase of RPF 
[6, 8], GFR [6]; decrease of FF [8], RVR [6]). In hyperten- 
sive patients RVR was decreased and PRF was increased 
after 20 mg nifedipine, whereas no effect was shown in 
normotensive patients [13]. In general, no consistent 
change in renal haemodynamics has been demonstrated 
after intake of dihydropyridine calcium antagonists [1]. 
Albumin excretion, a marker of glomerular per- 
meability, was unchanged after isradipine, and so were 
uric acid clearance and [32-microglobulin, markers of a 
proximal tubular effect. This does not support adominant 
proximal tubular natriuretic effect, as the mechanism of 
the isradipine-induced natriuresis. In contrast to these re- 
suits, Krusell et al. [6] and Pedersen et al. [7] demonstrated 
an increase in uric acid clearance in hypertensive patients 
after isradipine administration, suggesting a proximal tu- 
bular mechanism. In addition, the increase in lithium 
clearance [6] after isradipine treatment is thought o be a 
measure of increased proximal fluid output. Using the li- 
thium clearance method, an increase in absolute distal re- 
absorption of sodium after isradipine intake has been 
shown [6], which was thought to be compensatory for 
proximal loss. It has been hypothesized that calcium entry 
blockers induce their diuretic and natriuretic effects via a 
direct action on both proximal and distal tubular segments 
[1, 14]. The effect appears to be independent ofany vascu- 
lar action of the drugs [1], and the present results for is- 
radipine are in accordance with that assumption. 
PRA and PAC, as measures of a hormone system in- 
volved in regulation of intrarenal haemodynamics were 
unchanged (slight rend to increase in PRA at i h) after is- 
radipine intake. PRA in essential hypertensive patients 
was either increased [8, 9] or unchanged [3], and PAC was 
also unchanged [9]. There do not appear to be any reports 
about the renin-angiotensin system after isradipine ad- 
ministration to healthy controls. 
The differences between the present results and re- 
ports in the literature can be explained in part by the sub- 
jects studied, namely normotensive healthy controls in 
comparison to essential hypertensive patients [6-9] with 
differences in renal haemodynamics, especially hormonal 
regulation (angiotensin II, norepinephrine) [15, 16], and 
by the dose and mode of administration of isradipine: 
5 mg acutely in comparison to 2.8.75 mg [6], 2.6.65 mg/d 
[7], 2.7.5 mg [8] chronically, and 2.5, 5, 7.5 mg acutely [9]. 
Renal function in the present study was continuously 
monitored over 5 h as compared to a single measurement 
about 2 to 3 h after drug intake on other reports [6-9]. 
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Notwithstanding these differences, a common de- 
nominator for all these findings is that isradipine possesses 
natriuretic properties without compromising renal func- 
tion, and thereby has promising properties as an anti- 
hypertensive agent. 
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